Finding new drugs to treat pancreatic cancer
High Throughput Screening for SCAP Inhibitors as Pancreas Cancer Therapeutics
This study is looking for new treatments for pancreatic cancer by finding ways to block a protein that helps cancer cells grow, which could lead to better options for patients and improve their chances of living longer and feeling better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10866505 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic options for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer with limited treatment options. The approach involves high throughput screening to identify inhibitors of the SCAP protein, which is crucial for cancer cell growth and survival in nutrient-poor environments. By targeting SCAP, the research aims to disrupt the lipid supply that tumors need to grow and spread. Patients may benefit from new drugs that could improve survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced disease.
Not a fit: Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have performed: While the SREBP pathway has been studied in other cancers, this specific approach targeting SCAP in pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Espenshade, Peter J. — Johns Hopkins University
- Study coordinator: Espenshade, Peter J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.